Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC

Published:2014-08 Issue:8 Volume:18 Page:1519-1539
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J. Cell. Mol. Med.

Author:

Paz-Ares Luis¹,Soulières Denis²,Moecks Joachim³,Bara Ilze⁴,Mok Tony⁵,Klughammer Barbara⁶

Affiliation:

1. Department of Medical Oncology; Instituto de Biomedicina de Sevilla (HUVR, US and CSIC) and Hospital Universitario Virgen del Rocio; Seville Spain

2. Département de Médecine; Service d'hémato-oncologie; Centre Hospitalier de l'Université de Montréal; Montréal QC Canada

3. Department Bio-Mathematics; BIOMCON GmbH; Mannheim Germany

4. Global Medical Affairs Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland

5. Department of Clinical Oncology; The Chinese University of Hong Kong; Prince of Wales Hospital; Hong Kong China

6. Biomarker Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jcmm.12278/fullpdf

Reference119 articles.

1. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

2. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study;Cappuzzo;Lancet Oncol,2010

3. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

5. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer;Technology in Cancer Research & Treatment;2024-01

2. Immunoregulatory framework and the role of miRNA in the pathogenesis of NSCLC – A systematic review;Frontiers in Oncology;2022-12-21

3. Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-Mutated NSCLC Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis;Cancers;2022-07-11

4. Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis;JTO Clinical and Research Reports;2022-05

5. Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study;Therapeutic Advances in Medical Oncology;2022-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3